Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System

Yeramaneni et al., Gastroenterology, doi:10.1053/j.gastro.2020.10.011, Feb 2021
Mortality -24% improvement lower risk ← → higher risk Remdesivir  Yeramaneni et al.  LATE TREATMENT Is late treatment with remdesivir beneficial for COVID-19? Retrospective 7,158 patients in the USA (February - May 2020) No significant difference in mortality c19early.org Yeramaneni et al., Gastroenterology, Feb 2021 0 0.5 1 1.5 2+ RR
Retrospective 7,158 hospitalized COVID-19 patients in the USA analyzing famotidine treatment, showing no significant difference in mortality with associated remdesivir treatment.
Gérard, Zhou, Wu, Kamo, Choi, Kim show increased risk of acute kidney injury, Leo, Briciu, Muntean, Petrov show increased risk of liver injury, and Negru, Cheng, Mohammed show increased risk of cardiac disorders with remdesivir.
Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments14. Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
Important missing comments or errors? Let us know.
Study covers remdesivir and famotidine.
risk of death, 24.0% higher, OR 1.24, p = 0.87, treatment 32, control 7,126, adjusted per study, multivariable, day 30, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Yeramaneni et al., 28 Feb 2021, retrospective, USA, peer-reviewed, 6 authors, study period 11 February, 2020 - 8 May, 2020.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2025 USA Russia Sudan Angola Colombia Kenya Mozambique Vietnam Peru Philippines Spain Brazil Italy France Japan Canada China Uzbekistan Nepal Ethiopia Iran Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Bosnia-Herzegovina Ukraine Côte d'Ivoire Bulgaria Greece Slovakia Singapore Iceland New Zealand Czechia Mongolia Israel Trinidad and Tobago Hong Kong North Macedonia Belarus Qatar Panama Serbia CAR USA favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2025 USA Russia Sudan Angola Colombia Kenya Mozambique Vietnam Peru Philippines Spain Brazil Italy France Japan Canada China Uzbekistan Nepal Ethiopia Iran Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Ukraine Côte d'Ivoire Eritrea Bulgaria Greece Slovakia Singapore New Zealand Malawi Czechia Mongolia Israel Trinidad and Tobago North Macedonia Belarus Qatar Panama Serbia Syria USA favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System
Samrat Yeramaneni, Pratik Doshi, Kenneth Sands, Mandelin Cooper, Dax Kurbegov, Gregg Fromell
Gastroenterology, doi:10.1053/j.gastro.2020.10.011
P revious reports have found that in-hospital famotidine use in coronavirus disease 2019 (COVID-19) patients was associated with reduced risk of death or intubation. 1, 2 In 1 of these studies the authors proposed that famotidine inhibits the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protease, 3-chymotrypsin-like protease, that is essential for breakdown of the immature SARS-CoV-2 protein particles that contribute to the inflammatory response seen in some COVID-19-infected individuals, 1 which in turn can lead to acute respiratory distress syndrome, multiorgan dysfunction, physiologic deterioration, and death. 3 In a global pandemic with a lack of US Food and Drug Administration-approved targeted therapeutic agents, identification and repurposing of well-established drugs with a proven track record of safety, affordability, and widespread availability are necessary. 4 The purpose of this study was to evaluate the reported protective effect of famotidine on mortality in hospitalized COVID-19 patients.
Supplementary Material Note: To access the supplementary material accompanying this article, visit the online version of Gastroenterology at www.gastrojournal.org and at https://doi.org/10.1053/ j.gastro.2020.10.011. Conflicts of interest The authors disclose no conflicts.
References
Dr, Luther, Boulevard, Suite 800
Freedberg, None, Gastroenterology
Iacus, None, Political Analysis
Mather, None, Am J Gastroenterol
Rogosnitzky, None, JMIR Public Health Surveill
Wang, None, Lancet
Zhou, None, Lancet
DOI record: { "DOI": "10.1053/j.gastro.2020.10.011", "ISSN": [ "0016-5085" ], "URL": "http://dx.doi.org/10.1053/j.gastro.2020.10.011", "alternative-id": [ "S0016508520352495" ], "assertion": [ { "label": "This article is maintained by", "name": "publisher", "value": "Elsevier" }, { "label": "Article Title", "name": "articletitle", "value": "Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System" }, { "label": "Journal Title", "name": "journaltitle", "value": "Gastroenterology" }, { "label": "CrossRef DOI link to publisher maintained version", "name": "articlelink", "value": "https://doi.org/10.1053/j.gastro.2020.10.011" }, { "label": "Content Type", "name": "content_type", "value": "article" }, { "label": "Copyright", "name": "copyright", "value": "© 2021 by the AGA Institute" } ], "author": [ { "ORCID": "http://orcid.org/0000-0002-1411-2359", "affiliation": [], "authenticated-orcid": false, "family": "Yeramaneni", "given": "Samrat", "sequence": "first" }, { "affiliation": [], "family": "Doshi", "given": "Pratik", "sequence": "additional" }, { "affiliation": [], "family": "Sands", "given": "Kenneth", "sequence": "additional" }, { "affiliation": [], "family": "Cooper", "given": "Mandelin", "sequence": "additional" }, { "affiliation": [], "family": "Kurbegov", "given": "Dax", "sequence": "additional" }, { "affiliation": [], "family": "Fromell", "given": "Gregg", "sequence": "additional" } ], "container-title": [ "Gastroenterology" ], "content-domain": { "crossmark-restriction": true, "domain": [ "clinicalkey.jp", "clinicalkey.com", "gastrojournal.org", "clinicalkey.es", "clinicalkey.com.au", "clinicalkey.fr", "elsevier.com", "sciencedirect.com" ] }, "created": { "date-parts": [ [ 2020, 10, 12 ] ], "date-time": "2020-10-12T05:38:45Z", "timestamp": 1602481125000 }, "deposited": { "date-parts": [ [ 2021, 3, 20 ] ], "date-time": "2021-03-20T07:51:40Z", "timestamp": 1616226700000 }, "funder": [ { "DOI": "10.13039/100016646", "doi-asserted-by": "publisher", "name": "HCA Healthcare" } ], "indexed": { "date-parts": [ [ 2021, 12, 23 ] ], "date-time": "2021-12-23T22:27:20Z", "timestamp": 1640298440528 }, "is-referenced-by-count": 17, "issn-type": [ { "type": "print", "value": "0016-5085" } ], "issue": "3", "issued": { "date-parts": [ [ 2021, 2 ] ] }, "journal-issue": { "issue": "3", "published-print": { "date-parts": [ [ 2021, 2 ] ] } }, "language": "en", "license": [ { "URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 2, 1 ] ], "date-time": "2021-02-01T00:00:00Z", "timestamp": 1612137600000 } } ], "link": [ { "URL": "https://api.elsevier.com/content/article/PII:S0016508520352495?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://api.elsevier.com/content/article/PII:S0016508520352495?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining" } ], "member": "78", "original-title": [], "page": "919-921.e3", "prefix": "10.1053", "published": { "date-parts": [ [ 2021, 2 ] ] }, "published-print": { "date-parts": [ [ 2021, 2 ] ] }, "publisher": "Elsevier BV", "reference": [ { "DOI": "10.1053/j.gastro.2020.05.053", "author": "Freedberg", "doi-asserted-by": "crossref", "first-page": "1129", "journal-title": "Gastroenterology", "key": "10.1053/j.gastro.2020.10.011_bib1", "volume": "159", "year": "2020" }, { "DOI": "10.14309/ajg.0000000000000832", "author": "Mather", "doi-asserted-by": "crossref", "first-page": "1617", "journal-title": "Am J Gastroenterol", "key": "10.1053/j.gastro.2020.10.011_bib2", "volume": "115", "year": "2020" }, { "DOI": "10.1016/S0140-6736(20)30566-3", "author": "Zhou", "doi-asserted-by": "crossref", "first-page": "1054", "journal-title": "Lancet", "key": "10.1053/j.gastro.2020.10.011_bib3", "volume": "395", "year": "2020" }, { "DOI": "10.2196/19199", "author": "Rogosnitzky", "doi-asserted-by": "crossref", "journal-title": "JMIR Public Health Surveill", "key": "10.1053/j.gastro.2020.10.011_bib4", "volume": "6", "year": "2020" }, { "DOI": "10.1093/pan/mpr013", "author": "Iacus", "doi-asserted-by": "crossref", "first-page": "1", "journal-title": "Political Analysis", "key": "10.1053/j.gastro.2020.10.011_bib5", "volume": "20", "year": "2012" }, { "DOI": "10.1016/S0140-6736(20)31022-9", "author": "Wang", "doi-asserted-by": "crossref", "first-page": "1569", "journal-title": "Lancet", "key": "10.1053/j.gastro.2020.10.011_bib6", "volume": "395", "year": "2020" }, { "journal-title": "N Engl J Med", "key": "10.1053/j.gastro.2020.10.011_bib7", "year": "2020" } ], "reference-count": 7, "references-count": 7, "relation": {}, "score": 1, "short-container-title": [ "Gastroenterology" ], "short-title": [], "source": "Crossref", "subject": [ "Gastroenterology", "Hepatology" ], "subtitle": [], "title": [ "Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System" ], "type": "journal-article", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "volume": "160" }
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0